SCHEMBL12372520

SCHEMBL12372520

N#Cc1cc(Cl)cc(N2CCCC2)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRB1 P08588 2/20 0.48
CHRM2 P08172 1/20 0.48
CHRM4 P08173 1/20 0.48
CHRM1 P11229 1/20 0.48
CHRM3 P20309 1/20 0.48
DRD2 P14416 3/20 0.41
DRD3 P35462 2/20 0.41
CHRNB2 P17787 2/20 0.40
CHRNA4 P43681 2/20 0.40
IP6K1 Q92551 1/20 0.38
IP6K3 Q96PC2 1/20 0.38
IP6K2 Q9UHH9 1/20 0.38
CHRNA1 P02708 1/20 0.38
CHRNA7 P36544 1/20 0.38
KDM4E B2RXH2 3/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
ALDH1A1 P00352 1/20 0.38
TP53 P04637 2/20 0.37
DRD4 P21917 1/20 0.36
FADS1 O60427 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25762579 0.98 CHRM2 (0.47) ADRB1CHRM2CHRM4CHRM1CHRM3
SCHEMBL4758228 0.84 MAPK1 (0.47) ADRB1CHRM2CHRM4CHRM1CHRM3
SCHEMBL546950 0.84 CHRM2 (0.44) ADRB1CHRM2CHRM4CHRM1CHRM3
SCHEMBL31703179 0.84 MAPK1 (0.47) ADRB1CHRM2CHRM4CHRM1CHRM3
SCHEMBL16966425 0.82 CHRM2 (0.42) ADRB1CHRM2CHRM4CHRM1CHRM3
SCHEMBL2273801 0.80 ADRB1 (0.58) ADRB1CHRM2CHRM4CHRM1CHRM3
SCHEMBL9829419 0.80 ADRB1 (0.64) ADRB1CHRM2CHRM4CHRM1CHRM3
SCHEMBL28017895 0.78 DRD2 (0.62) ADRB1DRD2DRD3KDM4EALDH1A1
SCHEMBL3759138 0.78 DRD2 (0.41) DRD2DRD3CHRNB2CHRNA4IP6K1
SCHEMBL3752425 0.76 DRD2 (0.40) DRD2DRD3CHRNB2CHRNA4IP6K1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2245033-B1 PYRROLOPYRAZINE KINASE INHIBITORS HOFFMANN LA ROCHE (CH) 2011-08-31 EP disclosed
US-8008298-B2 Pyrrolopyrazine kinase inhibitors Roche Palo Alto (US) 2011-08-30 US disclosed
US-8008298-B2 Pyrrolopyrazine kinase inhibitors Roche Palo Alto (US) 2011-08-30 US disclosed
US-20100267666-A1 Pyrrolopyrazine kinase inhibitors ROCHE PALO ALTO LLC 2010-10-21 US disclosed
US-20100267666-A1 Pyrrolopyrazine kinase inhibitors ROCHE PALO ALTO LLC 2010-10-21 US disclosed
WO-2009106441-A1 PYRROLOPYRAZINE KINASE INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2009-09-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100267666-A1 Pyrrolopyrazine kinase inhibitors SYK, ZAP70, TYK2 ADRB1 3821/4885CHRM2 4129/4885CHRM4 4350/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.